Revenue

Financials in millions DKK. Fiscal year is January - December.

Millions DKK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Rybelsus Revenue	21.51B	22.09B	23.30B
Rybelsus Revenue Growth	-2.63%	-5.18%	24.27%
Ozempic Revenue	134.85B	127.09B	120.34B
Ozempic Revenue Growth	6.11%	5.61%	25.73%
Victoza Revenue	4.94B	3.02B	5.48B
Victoza Revenue Growth	63.64%	-44.91%	-36.73%
Total GLP-1 Revenue	161.30B	152.20B	149.13B
Total GLP-1 Revenue Growth	5.98%	2.06%	21.11%
Long-Acting Insulin Revenue	21.48B	18.76B	19.10B
Long-Acting Insulin Revenue Growth	14.52%	-1.78%	28.11%
Premix Insulin Revenue	10.14B	10.32B	10.79B
Premix Insulin Revenue Growth	-1.72%	-4.39%	12.69%
Fast-Acting Insulin Revenue	20.41B	18.58B	18.52B
Fast-Acting Insulin Revenue Growth	9.83%	0.33%	16.13%
Human Insulin Revenue	4.90B	5.48B	6.97B
Human Insulin Revenue Growth	-10.70%	-21.29%	-8.26%
Total Insulin Revenue	56.92B	53.14B	55.37B
Total Insulin Revenue Growth	7.13%	-4.04%	15.31%
Other Diabetes Care Revenue	1.86B	1.77B	2.12B
Other Diabetes Care Revenue Growth	4.92%	-16.51%	-8.30%
Total Diabetes Care Revenue	220.08B	207.11B	206.62B
Total Diabetes Care Revenue Growth	6.26%	0.24%	19.11%
Wegovy Revenue	84.52B	79.11B	58.21B
Wegovy Revenue Growth	6.84%	35.91%	85.71%
Saxenda Revenue	2.75B	3.24B	6.94B
Saxenda Revenue Growth	-15.12%	-53.30%	-32.55%
Total Obesity Care Revenue	87.27B	82.35B	65.15B
Total Obesity Care Revenue Growth	5.97%	26.40%	56.48%
Diabetes & Obesity Care Revenue	307.35B	289.46B	271.76B
Diabetes & Obesity Care Revenue Growth	6.18%	6.51%	26.34%
Rare Blood Disorders Revenue	11.67B	11.96B	12.14B
Rare Blood Disorders Revenue Growth	-2.41%	-1.51%	3.07%
Rare Endocrine Disorders Revenue	7.04B	5.96B	4.99B
Rare Endocrine Disorders Revenue Growth	18.14%	19.35%	30.16%
Other Rare Disease Revenue	1.74B	1.69B	1.51B
Other Rare Disease Revenue Growth	2.89%	12.33%	-2.77%
Rare Disease Revenue	20.45B	19.61B	18.64B
Rare Disease Revenue Growth	4.29%	5.20%	8.60%
Revenue (Total)	327.80B	309.06B	290.40B
Revenue (Total) Growth	6.06%	6.43%	25.03%

Revenue by Geography

Financials in millions DKK. Fiscal year is January - December.

Millions DKK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
US Revenue	-	173.17B	167.40B
US Revenue Growth	-	3.44%	31.26%
EUCAN Revenue	-	66.09B	57.55B
EUCAN Revenue Growth	-	14.85%	19.52%
Emerging Markets Revenue	-	30.44B	29.52B
Emerging Markets Revenue Growth	-	3.12%	19.09%
APAC Revenue	-	20.71B	17.44B
APAC Revenue Growth	-	18.78%	15.42%
China Revenue	-	18.66B	18.50B
China Revenue Growth	-	0.85%	10.87%
Total International Revenue	-	135.90B	123.00B
Total International Revenue Growth	-	10.48%	17.45%
Revenue (Total)	327.80B	309.06B	290.40B
Revenue (Total) Growth	6.06%	6.43%	25.03%

Revenue by Geography 2

Financials in millions DKK. Fiscal year is January - December.

Millions DKK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
US Revenue (Pre-FY2024 Reporting)	-	173.17B	167.40B
US Revenue (Pre-FY2024 Reporting) Growth	-	3.44%	31.26%
Other North American Operations (NAO) Revenue	-	-	10.77B
Other North American Operations (NAO) Revenue Growth	-	-	18.42%
Total North American Operations (NAO) Revenue	-	-	178.17B
Total North American Operations (NAO) Revenue Growth	-	-	30.41%
EMEA Revenue	-	-	60.40B
EMEA Revenue Growth	-	-	18.75%
China Revenue (Pre-FY2024 Reporting)	-	18.66B	18.50B
China Revenue (Pre-FY2024 Reporting) Growth	-	0.85%	10.87%
Rest of World Revenue	-	-	33.33B
Rest of World Revenue Growth	-	-	18.70%
Revenue (Total)	327.80B	309.06B	290.40B
Revenue (Total) Growth	6.06%	6.43%	25.03%

EBIT

Financials in millions DKK. Fiscal year is January - December.

Millions DKK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Diabetes & Obesity Care Operating Profit	146.20B	126.45B	127.72B
Diabetes & Obesity Care Operating Profit Growth	15.62%	-1.00%	28.20%
Rare Disease Operating Profit	2.29B	1.21B	620.00M
Rare Disease Operating Profit Growth	88.61%	95.48%	-78.99%
Operating Income (Total)	148.49B	127.66B	128.34B
Operating Income (Total) Growth	16.31%	-0.53%	25.12%

Updated May 6, 2026. Data Source: Fiscal.ai.